Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis

摘要: Background Pruritus has been anecdotally described in association with targeted cancer therapies. The risk of pruritus not systematically ascertained. Objective A systematic review and meta-analysis the literature was conducted for axitinib, cetuximab, dasatinib, erlotinib, everolimus, gefitinib, imatinib, ipilimumab, lapatinib, nilotinib, panitumumab, pazopanib, rituximab, sorafenib, temsirolimus, tositumomab, vandetanib, vemurafenib. Methods Databases from PubMed, Web Science (January 1998 through July 2012), American Society Clinical Oncology abstracts (2004 2012) were searched. Incidence relative risk calculated using random- or fixed-effects model. Results The incidences all-grade high-grade 17.4% (95% confidence interval 16.0%-19.0%) 1.4% 1.2%-1.6%), respectively. There an increased (relative 2.90 [95% 1.76-4.77, P Limitations reporting may vary, resulting concomitant medications, comorbidities, underlying malignancies. We found a higher incidence patients solid tumors, concordant those therapies highest incidences. Conclusion is significant developing receiving To prevent suboptimal dosing decreased quality life, should be counseled treated against this untoward symptom.